SHIJIAZHUANG, China, April 15, 2020 /PRNewswire/ -- On April 14, 2020, Yiling Pharmaceutical announced that Yiling Pharmaceutical and its subsidiary Beijing Yiling Pharmaceutical had received the approval document of drug supplement application concerning the application for new indications of Lianhua Qingwen capsules and Lianhua Qingwen granules issued by State Drug Administration. Lianhua Qingwen capsule and Lianhua Qingwen granules were approved to add "functional indications" to the originally approved indications: "In the conventional treatment of novel coronavirus pneumonia, it can be used for a light, common type of fever, cough, and fatigue", "Usage and dosage" increased "COVID-19 light, normal treatment for 7-10 days" and so on.
In this domestic epidemic, Lianhua Qingwen capsules (granules) became the most frequently recommended Chinese patent medicine for COVID 19. In the fourth to the seventh edition of the novel pneumonia diagnosis and treatment scheme infected by coronavirus published by the state health commission and the state administration of traditional Chinese medicine, it is recommended to take the Chinese patent medicine Lianhua Qingwen capsule (granule) for the prevention and treatment of patients with fatigue and fever during the medical observation period.
shaolingongfu.com was founded in China in 1996. The company has four divisions: Shaolin Services, Publication Services, Translation Services and Design Services.